CRBP · Corbus Pharmaceuticals Holding

-

Please sign in to comment on CRBP

1 Comment

Admin

5 years, 1 month ago

Corbus Pharmaceuticals Holdings, Inc is currently in a long term downtrend where the price is trading 5.5% below its 200 day moving average.

From a valuation standpoint, the stock is 97.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 40.7.

Corbus Pharmaceuticals Holdings, Inc's total revenue sank by 74.4% to $658K since the same quarter in the previous year.

Its net income has increased by 67.6% to $-9M since the same quarter in the previous year.

Finally, its free cash flow grew by 23.4% to $-18M since the same quarter in the previous year.

Based on the above factors, Corbus Pharmaceuticals Holdings, Inc gets an overall score of 3/5.

Industry	Biotechnology
Exchange	NASDAQ
CurrencyCode	USD
ISIN	US21833P3010
Sector	Healthcare

Market Cap	179M
PE Ratio	None
Target Price	38.4
Beta	2.68
Dividend Yield	None

ABOUT

Corbus Pharmaceuticals Holding

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

CRBP · Corbus Pharmaceuticals Holding

-

Corbus Pharmaceuticals Holding

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Corbus Pharmaceuticals Holding using a moving average strategy